Osivax
Osivax develops a new class of universal vaccines using its proprietary oligoDOM self-assembling nanoparticle platform technology. The platform is designed to trigger potent T-cell responses against highly conserved internal antigens to protect against constantly mutating pathogens. The company's lead clinical candidates include OVX836 for influenza and OVX033 for coronavirus infections.
Biotechnology
Healthcare
Vaccines
Infectious Diseases
Funding summary
- Total raised
- €50.1M
- Funding rounds
- 3
Investors in Osivax
Investors on record for Osivax. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Osivax?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors